The first clinical trial to explore the impact of IL-12 CAR-T cells has been opened by MSKCC (NCT02498912), where IL-12-secreting CAR-T cells transduced with a 28ζ CAR targeting mucin-16 (MUC-16) is being tested in patients with ovarian cancer. This evidence concerns the gene MUC16 and ovarian cancer.